Der Internist

, Volume 46, Issue 12, pp 1360–1366 | Cite as

Therapie und Prophylaxe rezidivierender Harnwegsinfekte

Schwerpunkt: Was ist gesichert in der Therapie?
  • 167 Downloads

Zusammenfassung

Rezidivierende Harnwegsinfekte sind typische Erkrankungen sexuell aktiver, junger Frauen. Nur bei älteren Frauen finden sich gehäuft zumeist urologische Grunderkrankungen. Neben Veränderungen der Lebensgewohnheiten ist die antibiotische Langzeitbehandlung bis heute Eckpfeiler der Prophylaxe und Therapie. Der vorliegende Beitrag erläutert kurz die Pathogenese und Risikofaktoren von rezidivierenden Harnwegsinfekten, sowie Strategien zu deren Prävention. Der aktuelle Stellenwert von pflanzlichen Wirkstoffen und Antibiotika wird diskutiert, unwirksame Therapieansätze werden erklärt. Schließlich weist ein Ausblick auf die in Entwicklung befindlichen und z. T. schon in klinischen Studien angewandten Impfstoffe als vielversprechende, zukünftige Therapieoption hin.

Schlüsselwörter

Rezidivierender Harnwegsinfekt Antibiotikatherapie Antibiotikaprophylaxe Impfung 

Treatment and prophylaxis of recurrent urinary tract infections

Abstract

Recurrent urinary tract infections are typical diseases of sexually active young women. Only elder women show significant rates of underlying, mostly urological diseases. Besides behavioral changes long-term antimicrobial therapy is still the mainstay of both prophylaxis and therapy. This report provides information on the etiology for recurrent urinary tract infections. Strategies for prevention are illustrated. The actual significances of organic remedies and antibiotics respectively are discussed; ineffective therapies are identified. Furthermore an outlook is given on promising novel therapeutics, i.e. vaccines which are already tested in clinical trials.

Keywords

Urinary tract infection Antibiotic therapy Antibiotic prophylaxis Vaccine 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Literatur

  1. 1.
    Foxman B, Gillespie B, Koopman J et al. (2000) Risk factors for second urinary tract infection among college women. Am J Epidemiol 151: 1194–1205PubMedGoogle Scholar
  2. 2.
    Zorc JJ, Kiddoo DA, Shaw KN (2005) Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 18: 417–422CrossRefPubMedGoogle Scholar
  3. 3.
    Lipsky BA (1999) Prostatitis and urinary tract infection in men: what’s new; what’s true? Am J Med 106: 327–334CrossRefPubMedGoogle Scholar
  4. 4.
    Ronald A (2003) The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 49: 71–82CrossRefPubMedGoogle Scholar
  5. 5.
    Johnson JR (2003) Microbial virulence determinants and the pathogenesis of urinary tract infection. Infect Dis Clin North Am 17: 261–278CrossRefPubMedGoogle Scholar
  6. 6.
    Anders HJ, Banas B, Schlondorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15: 854–867CrossRefPubMedGoogle Scholar
  7. 7.
    Chowdhury P, Sacks SH, Sheerin NS (2004) Minireview: functions of the renal tract epithelium in coordinating the innate immune response to infection. Kidney Int 66: 1334–1344CrossRefPubMedGoogle Scholar
  8. 8.
    Kunin CM, White LV, Hua TH (1993) A reassessment of the importance of „low-count“ bacteriuria in young women with acute urinary symptoms. Ann Intern Med 119: 454–460PubMedGoogle Scholar
  9. 9.
    Fowler JE, Pulaski ET (1981) Excretory urography, cystography, and cystoscopy in the evaluation of women with urinary-tract infection: a prospective study. N Engl J Med 304: 462–465PubMedGoogle Scholar
  10. 10.
    Hooton TM, Scholes D, Hughes JP et al. (1996) A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 335: 468–474CrossRefPubMedGoogle Scholar
  11. 11.
    Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, Rottensterich E, Stamm WE (2000) Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 30: 152–156CrossRefPubMedGoogle Scholar
  12. 12.
    Stapleton A, Nudelman E, Clausen H, Hakomori S, Stamm WE (1992) Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status. J Clin Invest 90: 965–972PubMedGoogle Scholar
  13. 13.
    Godaly G, Bergsten G, Hang L et al. (2001) Neutrophil recruitment, chemokine receptors, and resistance to mucosal infection. J Leukoc Biol 69: 899–906PubMedGoogle Scholar
  14. 14.
    Wang X, Sun H, Fan Y, Li L, Makino T, Kano Y (2005) Analysis and bioactive evaluation of the compounds absorbed into blood after oral administration of the extracts of Vaccinium vitis-idaea in rat. Biol Pharm Bull 28: 1106–1108CrossRefPubMedGoogle Scholar
  15. 15.
    Jepson RG, Mihaljevic L, Craig J (2004) Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev: CD001321Google Scholar
  16. 16.
    Suvarna R, Pirmohamed M, Henderson L (2003) Possible interaction between warfarin and cranberry juice. BMJ 327: 1454CrossRefPubMedGoogle Scholar
  17. 17.
    Ikaheimo R, Siitonen A, Heiskanen T, Karkkainen U, Kuosmanen P, Lipponen P, Makela PH (1996) Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 22: 91–99PubMedGoogle Scholar
  18. 18.
    Stamey TA, Sexton CC (1975) The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections. J Urol 113: 214–217PubMedGoogle Scholar
  19. 19.
    Raz R, Stamm WE (1993) A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329: 753–756CrossRefPubMedGoogle Scholar
  20. 20.
    Albert X, Huertas I, Pereiro II, Sanfelix J, Gosalbes V, Perrota C (2004) Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev: CD001209Google Scholar
  21. 21.
    Stamm WE, McKevitt M, Roberts PL, White NJ (1991) Natural history of recurrent urinary tract infections in women. Rev Infect Dis 13: 77–84PubMedGoogle Scholar
  22. 22.
    Chan RC, Reid G, Irvin RT, Bruce AW, Costerton JW (1985) Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infect Immun 47: 84–89PubMedGoogle Scholar
  23. 23.
    Asahara T, Nomoto K, Watanuki M, Yokokura T (2001) Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 45: 1751–1760CrossRefPubMedGoogle Scholar
  24. 24.
    Langermann S, Mollby R, Burlein JE et al. (2000) Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 181: 774–778CrossRefPubMedGoogle Scholar
  25. 25.
    Li X, Erbe JL, Lockatell CV, Johnson DE, Jobling MG, Holmes RK, Mobley HL (2004) Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect Immun 72: 7306–7310CrossRefPubMedGoogle Scholar
  26. 26.
    Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE (2003) Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol 170: 867–869CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Innere Medizin II — NephrologieUniversität Regensburg
  2. 2.Klinik und Poliklinik für Innere Medizin II — NephrologieKlinikum der UniversitätRegensburg

Personalised recommendations